市場調查報告書
商品編碼
1280665
溫和細胞解離試劑市場規模、市場份額、應用分析、區域展望、增長趨勢、主要參與者、競爭戰略和預測,2023-2031 年Gentle Cell Dissociation Reagent Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031 |
友好的細胞解離試劑市場是生命科學行業中一個不斷增長的市場。 溫和細胞解離試劑是一種無□解離試劑,可用於解離多種類型的細胞,包括原代細胞、幹細胞和腫瘤細胞。 由於對基於細胞的研究和細胞治療的需求不斷增加,預計未來幾年溫和細胞解離試劑市場將增長。 在 2023 年至 2031 年的預測期內,該市場預計將以 6.5% 的複合年增長率增長。 越來越多地採用基於細胞的藥物發現分析和慢性病患病率上升是推動市場增長的主要因素。
擴大對基於細胞的研究的需求
基於細胞的研究已成為藥物發現和開發的一個組成部分。 由於需要更準確、更有效地測試候選藥物,對基於細胞的檢測的需求正在增加。 因此,對溫和細胞解離試劑的需求正在增加。 對基於細胞的檢測的需求增加預計將推動友好的細胞解離試劑市場的增長。
慢性病患病率上升
癌症、神經系統疾病和心血管疾病等慢性病患病率的上升正在推動對基於細胞的療法的需求。 溫和細胞解離試劑用於分離和擴增用於細胞療法的干細胞。 根據 Grand View Research 的一份報告,慢性病患病率的上升將推動全球幹細胞治療市場的增長,這有望帶動溫和細胞解離試劑市場的增長。
生物技術和製藥行業的進步
近年來,生物技術和製藥行業取得了重大進展。 由於對研發活動的投資增加,正在開發創新藥物和治療方法。 溫和細胞解離試劑在藥物發現和開發過程中至關重要,對創新藥物不斷增長的需求有望推動溫和細胞解離試劑市場的增長。 根據 Zion Market Research 的一份報告,生物技術和製藥行業的投資增加有望推動全球友好型細胞解離試劑市場的增長。
易解離試劑認知度低、成本高
儘管對溫和細胞解離試劑的需求不斷增加,但這些試劑的認知度低和成本高是市場的製約因素。 許多研究人員沒有意識到溫和細胞解離試劑的好處,並繼續使用苛刻的細胞解離方法。 此外,與傳統方法相比,溫和細胞解離試劑的高成本限制了它們的採用。 高成本可能是由於使用了高質量的□和其他試劑。 此外,使用溫和的細胞解離試劑需要特定的協議和設備,並且可能需要額外的投資。 溫和細胞解離試劑的低意識和高成本預計會阻礙市場增長。 他們還指出,製造商需要提高研究人員和研發人員對溫和細胞解離試劑的好處的認識,並開發具有成本效益的試劑來解決這一抑制因素。
結締組織部門主導收入份額
結締組織將在 2022 年佔據最大的收入份額,因為在從各種結締組織中分離和培養細胞時越來越多地使用溫和的細胞解離試劑。 結締組織細胞在各種器官和組織的研究和開發中發揮著重要作用,其分離和培養在多項生物醫學研究中必不可少。 另一方面,預計在 2023-2031 年的預測期內,上皮組織部分將以最高複合年增長率增長。 上皮細胞是排列在各種器官和組織中的主要細胞,它們的分離和培養在多項生物醫學研究中至關重要。 出於研究目的對上皮細胞的需求不斷增加,預計將推動溫和細胞解離試劑市場的增長。
實驗室部門主導收入份額
由於在細胞分離和培養的各種實驗程序中越來越多地使用溫和的細胞解離試劑,到 2022 年,實驗室部分將佔市場的最大收入份額。 藥物發現和開發、癌症研究和其他生物醫學研究對基於細胞的檢測的需求不斷增長,預計將推動該領域的市場增長。 在預測期內,醫院部門預計將以最高複合年增長率增長。 癌症等慢性病患病率的增加以及對個性化醫療的需求不斷增長,預計將推動該領域溫和細胞解離試劑市場的增長。 醫院和診所越來越多地採用溫和的細胞解離試劑來分離和培養用於診斷和治療目的的細胞。
北美引領收入,亞太地區引領市場增長
由於該地區存在大量生物技術和製藥公司、學術和研究機構以及醫院,到 2022 年,北美將佔據最大的市場份額。 在藥物發現開發、癌症研究和其他生物醫學研究中越來越多地採用基於細胞的檢測方法,預計將推動該地區的市場增長。 此外,癌症和自身免疫性疾病等慢性病患病率的增加預計也將推動該地區的市場增長。 在 2023-2031 年的預測期內,亞太地區預計將以最高複合年增長率增長。 專注於生物醫學研發、增加對醫療基礎設施的投資以及該地區慢性病患病率上升預計將推動該地區的市場增長。 此外,越來越多地採用個性化醫療以及對用於藥物發現和藥物開發的基於細胞的檢測的需求不斷增加,預計也將推動該地區的市場增長。
預計在預測期內競爭將加劇
友好細胞解離試劑的全球市場競爭激烈,其特點是存在多家大型企業。 市場上的主要參與者包括 Thermo Fisher Scientific, Inc、Merck KGaA、STEMCELL Technologies、ATCC、MiltenyiBiotec GmbH、Biological Industries、PromoCell GmbH、Corning Incorporated、Lonza、HiMedia Laboratories 以及我擁有的其他知名參與者。 這些公司積極參與併購、聯盟、合作夥伴關係和產品發布等戰略舉措,以加強其市場地位。 例如,2021 年 5 月,Thermo Fisher Scientific, Inc. 宣布推出其下一代細胞療法製造平台,即新型 Gibco CTS Rotea 逆流離心系統。 該平台包括一系列針對細胞和基因治療製造優化的友好細胞解離試劑。 對個性化醫療的日益關注、藥物發現和開發中對基於細胞的檢測的需求不斷增加以及慢性病患病率的上升預計將在預測期內推動市場增長。
本報告中回答的關鍵問題
影響友好型細胞解離試劑市場增長的關鍵微觀和宏觀環境因素有哪些?
現在和預測期內,產品細分和地區的主要投資領域是什麼?
到 2031 年的估計和市場預測
在預測期內,哪些細分市場的複合年增長率最快?
哪個細分市場的市場份額更大,為什麼?
低收入和中等收入國家是否正在投資友好的細胞解離試劑市場?
哪個地區的細胞溫和解離試劑市場規模最大?
亞太、拉丁美洲、中東和非洲等新興市場的市場趨勢和動態如何?
推動友好型細胞解離試劑市場增長的主要趨勢是什麼?
主要競爭對手及其在全球友好型細胞解離試劑市場中增加影響力的關鍵戰略是什麼?
The gentle cell dissociation reagent market is a growing market in the life sciences industry. The gentle cell dissociation reagent is a type of enzyme-free dissociation reagent that can be used to dissociate various cell types, including primary cells, stem cells, and tumor cells. The market for gentle cell dissociation reagents is expected to grow in the coming years due to the increasing demand for cell-based research and cell therapy. The market Is expected to grow at a CAGR of 6.5% during the forecast period of 2023 to 2031. The increasing adoption of cell-based assays for drug discovery and the rising prevalence of chronic diseases are some of the key factors driving the growth of the market.
Cell-based research has become an essential part of drug discovery and development. The demand for cell-based assays has been increasing due to the need for a more accurate and efficient way of testing drug candidates. Gentle cell dissociation reagents are crucial in the process of isolating cells from tissues, enabling researchers to obtain a homogenous cell population for experiments. As a result, the demand for gentle cell dissociation reagents has been increasing. Increasing demand for cell-based assays is expected to drive the growth of the gentle cell dissociation reagent market.
The rising prevalence of chronic diseases, such as cancer, neurological disorders, and cardiovascular diseases, has been driving the demand for cell-based therapies. Gentle cell dissociation reagents are used in the isolation and expansion of stem cells, which are used in cell-based therapies. According to a report by Grand View Research, the increasing prevalence of chronic diseases is expected to drive the growth of the global stem cell therapy market, which in turn is expected to drive the growth of the gentle cell dissociation reagent market.
The biotechnology and pharmaceutical industries have been witnessing significant advancements in recent years. The increasing investment in research and development activities has resulted in the development of innovative drugs and therapies. Gentle cell dissociation reagents are crucial in the process of drug discovery and development, and the increasing demand for innovative drugs is expected to drive the growth of the gentle cell dissociation reagent market. According to a report by Zion Market Research, the increasing investment in the biotechnology and pharmaceutical industries is expected to drive the growth of the global gentle cell dissociation reagent market.
Despite the increasing demand for gentle cell dissociation reagents, the market is restrained by limited awareness and the high cost of these reagents. Many researchers and laboratories are not aware of the benefits of gentle cell dissociation reagents, and therefore, continue to use harsh methods of cell dissociation. Additionally, the cost of gentle cell dissociation reagents is higher compared to traditional methods, which limits their adoption. The high cost of these reagents can be attributed to the use of high-quality enzymes and other reagents in their formulation. Furthermore, the use of gentle cell dissociation reagents requires specific protocols and equipment, which may require additional investment. The limited awareness and high cost of gentle cell dissociation reagents are expected to hinder the growth of the market. The report also suggests that manufacturers need to increase awareness among researchers and laboratories about the benefits of gentle cell dissociation reagents and develop cost-effective reagents to address this restraint.
Connective tissue held the largest revenue share in 2022, owing to the increasing use of gentle cell dissociation reagents in the isolation and culture of cells from various connective tissues. Connective tissue cells play a vital role in the development of various organs and tissues, making their isolation and culture essential in several biomedical research studies. On the other hand, the epithelial tissue segment is expected to grow at the highest CAGR during the forecast period of 2023 to 2031. Epithelial cells are the primary cells that line various organs and tissues, and their isolation and culture are crucial in several biomedical research studies. The increasing demand for epithelial cells for research purposes is expected to drive the growth of the gentle cell dissociation reagent market.
The laboratory segment held the largest revenue share of the market in 2022, owing to the increasing use of gentle cell dissociation reagents in various laboratory procedures for the isolation and culture of cells. The rising demand for cell-based assays in drug discovery and development, cancer research, and other biomedical studies is expected to drive the growth of the market in this segment. The hospital segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of chronic diseases such as cancer and the rising demand for personalized medicine is expected to drive the growth of the gentle cell dissociation reagent market in this segment. Hospitals and clinics are increasingly adopting gentle cell dissociation reagents for the isolation and culture of cells for diagnosis and treatment purposes.
North America held the largest share of the market in 2022, owing to the presence of a large number of biotechnology and pharmaceutical companies, academic and research institutes, and hospitals in the region. The increasing adoption of cell-based assays in drug discovery and development, cancer research, and other biomedical studies is expected to drive the growth of the market in this region. Additionally, the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is also expected to drive the growth of the market in this region. Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2023 to 2031. The increasing focus on biomedical research and development, growing investments in healthcare infrastructure, and the rising prevalence of chronic diseases in the region are expected to drive the growth of the market in this region. The increasing adoption of personalized medicine and the growing demand for cell-based assays for drug discovery and development is also expected to drive the growth of the market in this region.
The global gentle cell dissociation reagent market is highly competitive and is characterized by the presence of several major players. Some of the key players operating in the market include Thermo Fisher Scientific, Inc., Merck KGaA, STEMCELL Technologies, ATCC, MiltenyiBiotec GmbH, Biological Industries, PromoCell GmbH, Corning Incorporated, Lonza, HiMedia Laboratories and Other Notable Players. These companies are actively involved in strategic initiatives, such as mergers and acquisitions, collaborations, partnerships, and product launches, to strengthen their market position. For instance, in May 2021, Thermo Fisher Scientific, Inc. announced the launch of its new Gibco CTS Rotea Counterflow Centrifugation System, a next-generation cell therapy manufacturing platform. The platform includes gentle cell dissociation reagents that are optimized for the production of cell and gene therapies. The increasing focus on personalized medicine, the growing demand for cell-based assays in drug discovery and development, and the rising prevalence of chronic diseases are expected to drive the growth of the market during the forecast period.
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gentle Cell Dissociation Reagent market are as follows:
Micro and macro environment factors that are currently influencing the Gentle Cell Dissociation Reagent market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.